10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
NCT03090490 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68
Last updated 2020-01-14
Summary
This open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the ten years after antipsychotic discontinuation in a sample of functionally recovered first-episode patients with schizophrenia spectrum disorder.
Conditions
- Schizophrenia
- Schizophrenia Relapse
- Schizophrenia Spectrum and Other Psychotic Disorders
Interventions
- OTHER
-
Antipsychotic treatment discontinuation
Withdrawal of antipsychotic medication to stabilized patients
- OTHER
-
Maintenance treatment discontinuation
Maintenance antipsychotic medication to stabilized patients
Sponsors & Collaborators
-
Centro de Investigación Biomédica en Red de Salud Mental
collaborator NETWORK -
Instituto de Investigación Marqués de Valdecilla
collaborator OTHER -
Fundación Marques de Valdecilla
lead OTHER
Principal Investigators
-
Benedicto Crespo-Facorro, Professor · University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain. CIBERSAM Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 15 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-09-30
- Primary Completion
- 2017-12-31
- Completion
- 2020-12-31
Countries
- Spain
Study Locations
More Related Trials
-
Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia
NCT01724359 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
NCT00460512 ·Status: COMPLETED ·Phase: PHASE3
-
Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia
NCT03130465 ·Status: UNKNOWN
-
Paliperidone Palmitate Flexible Dosing in Schizophrenia
NCT01281527 ·Status: COMPLETED ·Phase: PHASE3
-
Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain
NCT03130478 ·Status: COMPLETED
-
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
NCT01009047 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia
NCT00757705 ·Status: COMPLETED ·Phase: PHASE4
-
Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia
NCT01726335 ·Status: COMPLETED ·Phase: PHASE4
-
A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.
NCT00668837 ·Status: COMPLETED ·Phase: PHASE3
-
A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode
NCT00378092 ·Status: COMPLETED ·Phase: PHASE4
-
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up
NCT02526030 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone
NCT01010776 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
NCT02713282 ·Status: COMPLETED ·Phase: PHASE3
-
Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations
NCT01181960 ·Status: COMPLETED
-
An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia
NCT00566631 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting
NCT01926912 ·Status: COMPLETED
-
A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.
NCT00086320 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
NCT02431702 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia
NCT01662310 ·Status: COMPLETED ·Phase: PHASE3
-
PREvent First Episode Relapse (PREFER)
NCT00220714 ·Status: UNKNOWN ·Phase: PHASE4
-
A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.
NCT00645307 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
NCT02305823 ·Status: COMPLETED ·Phase: PHASE4
-
Pan European Collaboration on Antipsychotic Naïve Schizophrenia II
NCT02339844 ·Status: COMPLETED ·Phase: PHASE4
-
Standard Comprehensive Intervention to Treat First-episode Schizophrenia
NCT01057849 ·Status: UNKNOWN ·Phase: NA
-
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia
NCT01559272 ·Status: COMPLETED ·Phase: PHASE1